1. Amberia, K., Nordberg, A., Viitanen, M., and Winblad B., 1993, Long-term treatment with tacrine (THA) in Alzheimer disease evaluation of neuropsychological data. Acta.Neurol.Scand: Suppl.149: 55–57.
2. Anand, R., Hartman, R.D., and Hayes, P.E., 1996, An overview of the development of SDZ ENA 713, a brain selective cholinesterase inhibitor. In: Alzheimer Disease: From Molecular Biology to Therapy. Becker, R. and Giacobini, E., eds., Boston: Birkhăuser. pp 239–243.
3. Becker, R., Colliver, J., and Elbe, R.,1990, Effects of Metrifonate, a long-acting cholinesterase inhibitor Drug Dev. Res. 19:425–434.
4. Becker, R., Moriearty, P., and Unni, L., 1991, The second generation of cholinesterase inhibitors: Clinical and pharmacological effects In: Cholinergic basis for Alzheimer Therapy, Becker, R. and Giacobini, E. eds., Boston: Birkhäuser, pp 263–296.
5. Becker, R., Colliver, J.A., Markwell, S.J., Moriearty, P., Unni, L.K., and Vicari S.,1996, Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor for Alzheimer disease. Alz. Dis. Assoc. Dis. 10:124–131.